A5102832210- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
- Axon Guidance and Neuronal Signaling
- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways
- Soil Moisture and Remote Sensing
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Family Support in Illness
- Cancer, Hypoxia, and Metabolism
- Childhood Cancer Survivors' Quality of Life
- Angiogenesis and VEGF in Cancer
- Cytomegalovirus and herpesvirus research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Mechanisms and Therapy
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
Anhui Medical University
2019-2024
Shanghai Jiao Tong University
2015-2024
Shanghai Chest Hospital
2015-2024
Changchun Normal University
2024
First Affiliated Hospital of Anhui Medical University
2019-2024
Luye Pharma (China)
2021-2024
Taizhou Vocational and Technical College
2024
Ten Chen Hospital
2022
Bridge University
2022
University of California, Los Angeles
2020
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768).Patients at 53 sites China were randomly assigned 1:1 to receive either (110 mg)...
Semaphorin 4B (SEMA4b) has been shown to play a substantial role in the invasion of non-small cell lung cancer (NSCLC). However, regulation mechanism SEMA4b is largely elusive. Here, we reported significant decrease level and increase MMP9 NSCLC compared with adjacent normal tissue from same patient. We thus used two human lines, A549 Calu-3, examine whether may affect expression NSCLC. found that overexpression significantly decreased level, while inhibition increased level. The adapted...
EGFR exon 20 insertions ( e20ins) account for up to 10% of mutations in lung cancer; however, tumors with e20ins had poor response rates tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib, and osimertinib, the heterogeneity further complicates clinical studies. Here, we retrospectively screened next‐generation sequencing (NGS) data from 24 468 cancer patients, a total 85 unique variants were identified 547 cases (2.24%), p.A767_V769dup (25.1%) p.S768_D770dup (17.6%)...
The initial randomized, double-blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). Metastatic disease the central nervous system (CNS) remains a challenge management of NSCLC. This aimed compare versus among patients with baseline CNS metastases study.
The objective of this study is to explore clinical risk factors for venous thromboembolism (VTE) in postoperative lung cancer patients order provide a basis the prevention and treatment VTE.A total 1,001 were retrospectively analyzed. Each patient was confirmed with surgical pathology diagnosis had complete follow-up record. VTE identified combination spiral computed tomography (CT), pulmonary angiography, color Doppler ultrasound. We used life table method create an occurrence frequency...
9013 Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. has been approved in China for treatment of patients (pts) mutant NSCLC T790M upon progression disease on previous TKIs (Proc. AACR 2020, Abstract CT190). This Phase III trial assessed the efficacy safety versus G as initial advanced EGFRm. Methods: Pts previously...
Purpose: Responses to EGFR -targeted therapy are generally temporary, due inevitable drug resistance. The prevalence and characteristics of receptortyrosine–kinase (RTK) fusion as acquired resistance tyrosine–kinase inhibitors (TKIs) rarely investigated. Methods: We retrospectively reviewed genomic profiling data 3873 (exons 18–21)-mutant lung cancer patients with more than once next-generation sequencing detection. A total 16 who RTK fusions during EGFR-TKI treatment paired pre-...
ABSTRACT Human herpesvirus 6 (HHV-6), a latent lymphotropic and neurotropic virus, has been suspected as an etiologic agent in multiple sclerosis (MS). The study was undertaken to correlate virologic evidence for HHV-6 activity with the state of host immunity MS patients control subjects. revealed that cell-free DNA detected more frequently both serum cerebrospinal fluid than those T cells recognizing recombinant 101-kDa protein (101K) corresponding major immunoreactive region unique...
Vasoactive intestinal peptide (VIP) has a unique property of regulating T(h)1 and T(h)2 immunity CD4+ T cells. In this study, we demonstrated, for the first time, that differential expression VIP receptors compensatory mechanism directly affect responsiveness cells their properties to VIP. The receptor-1 (VPAC1) VPAC2 in changed reciprocally context activation state. activated healthy individuals, markedly decreased VPAC1 was compensated by increased induced cell activation. contrast, there...
The ways patients cope with advanced cancer can influence their health-related quality of life (HRQoL). This study aims to examine the mediating role positive and negative mood in relationship between coping HRQoL lung cancer.A consecutive sample 261 (mean age: 59.99±9.53) diagnosed stage III or IV was recruited from inpatient unit a hospital that specialises chest-related disease Shanghai, China. Participants completed measurements including Medical Coping Modes Questionnaire, Positive...